Multidisciplinary management of gastric and gastroesophageal cancers

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 24

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

424

HTML

3885

Figures (1-2)

205

Tables (1-1)

200

Sum=4714

Jun 28, 2008 (publication date) through Nov 30, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jun 28, 2008; 14(24): 3773-3780
Published online Jun 28, 2008. doi: 10.3748/wjg.14.3773

Table 1 Ongoing important phase III clinical trials, including monoclonal antibodies and signal transduction/tyrosine kinase inhibitors

Name	Design	Indication
TOGA	XP or FP +/- trastuzumab	Advanced gastric cancer HER2-positive
AVAGAST	XP +/- bevacizumab	Metastatic gastric cancer
REAL-3	EOX +/- panitumumab	Advanced esophagogastric cancer
FFCD 03-07	ECX followed by FOLFIRI vs FOLFIRI followed by ECX	Advanced esophagogastric cancer
EXPAND	XP +/- Cetuximab	Advanced/Metastatic gastric cancer
MAGIC-B	Perioperative ECX +/- bevacizumab	Neo-adjuvant gastric cancer
CLASSIC	XELOX vs observation	Adjuvant gastric cancer

Citation: Moehler M, Lyros O, Gockel I, Galle PR, Lang H. Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol 2008; 14(24): 3773-3780
URL: https://www.wjgnet.com/1007-9327/full/v14/i24/3773.htm
DOI: https://dx.doi.org/10.3748/wjg.14.3773